The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $400,000 Project Grant to Navega Therapeutics, Inc., a San Diego-based biotechnology company, under the Drug Abuse and Addiction Research Programs (CFDA 93.279). The funding will support Navega's research and development efforts to advance novel epigenetic gene therapies targeting the voltage-gated sodium channel NAV1.7 for the treatment of chronic pain. This innovative approach aims to transiently repress NAV1.7 expression to provide non-addictive, long-lasting pain relief, addressing the significant unmet need for alternatives to opioid-based pain medications. The project's goal is to advance this therapeutic approach to the clinical stage and identify a strong industry partner to bring it to patients suffering from chronic pain conditions.
Generated 7/16/24, 10:08 AM